MY199104A - Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder - Google Patents

Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Info

Publication number
MY199104A
MY199104A MYPI2019003348A MYPI2019003348A MY199104A MY 199104 A MY199104 A MY 199104A MY PI2019003348 A MYPI2019003348 A MY PI2019003348A MY PI2019003348 A MYPI2019003348 A MY PI2019003348A MY 199104 A MY199104 A MY 199104A
Authority
MY
Malaysia
Prior art keywords
bipolar disorder
alleviation
prevention
treatment
carbamate compounds
Prior art date
Application number
MYPI2019003348A
Other languages
English (en)
Inventor
Yu Jin Shin
Sei Myoung Han
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MY199104A publication Critical patent/MY199104A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2019003348A 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder MY199104A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
MY199104A true MY199104A (en) 2023-10-13

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019003348A MY199104A (en) 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Country Status (14)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CL (1) CL2019001618A1 (enExample)
ES (1) ES3054693T3 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003203A (es) * 2018-09-21 2021-05-27 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico.
EP3854392A4 (en) * 2018-09-21 2022-08-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES
KR20220104746A (ko) * 2019-11-22 2022-07-26 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297732C (en) * 1997-08-14 2008-04-29 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
KR100843703B1 (ko) 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도
CZ20032300A3 (cs) * 2001-02-27 2005-01-12 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro prevenci nebo léčbu bipolárních chorob
HUP0303261A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating bipolar disorder
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CA2667909A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
BRPI0924997B1 (pt) 2009-06-22 2024-01-16 Sk Biopharmaceuticals Co., Ltd Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9981950B2 (en) * 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors

Also Published As

Publication number Publication date
EP3556366A1 (en) 2019-10-23
RU2019121913A (ru) 2021-01-15
JP2020502106A (ja) 2020-01-23
ZA201903747B (en) 2021-01-27
WO2018111008A1 (ko) 2018-06-21
KR102635938B1 (ko) 2024-02-13
CL2019001618A1 (es) 2019-08-23
AU2017374458B2 (en) 2023-03-02
US11571410B2 (en) 2023-02-07
RU2019121913A3 (enExample) 2021-04-21
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
IL267195A (enExample) 2019-07-31
KR20190087572A (ko) 2019-07-24
CA3046297A1 (en) 2018-06-21
BR112019011930A2 (pt) 2019-10-29
EP3556366B1 (en) 2025-10-22
CN110290788A (zh) 2019-09-27
US20190314337A1 (en) 2019-10-17
ES3054693T3 (en) 2026-02-05
IL267195B1 (en) 2024-01-01
MX2019006940A (es) 2019-09-06
AU2017374458A1 (en) 2019-07-04
JP7208139B2 (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
PH12021500034A1 (en) Compounds useful in hiv therapy
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MX395482B (es) Compuestos antiproliferativos y metodos de uso de los mismos
MY197698A (en) Oxysterols and methods of use thereof
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MY202884A (en) Compounds useful in hiv therapy
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
MX2017013281A (es) Metodos para tratar transtornos del almacenamiento lisosomal.
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
SG11201803867TA (en) Sodium channel blocker
PH12020550549A1 (en) Compositions for preventing or treating lupus
MY198417A (en) Use of Carbamate Compound for Preventing, Alleviating, or Treating Tremors or Tremor Syndrome